Keywords: Caelyx, Ceplene, Manufacturing facilities, Janssen-Cilag, Johnson & Johnson, EpiCept, Ben Venue Labs, EMA, Quality asurance, Boehringer Ingelheim
Caelyx and Ceplene manufacturing should be moved, says EMA
Article | 18 March 2012
The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines Caelyx (doxorubicin hydrochloride) from Johnson & ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
